However, similar to the pattern of amplification observed in patient samples and cancer cell lines, FGFR inhibitor–sensitive PDX specimens had FGFR1/NSD3-centered amplification, whereas FGFR-deficient samples showed no clear center of amplification (Figure 4D and Supplemental Figure 11). Here, NSD3 is linked to cancer.